KYORIN Pharmaceutical (4569) · InitiativeFirst statedLatest Earnings (2026-07-30): "Dropped"
Option Agreement with Cyrano for a Treatment for Post-Viral Olfactory Dysfunction
First written in FY2025. 1 of 2 entries say "Dropped", first in 2026-07-30. Latest entry: 2026-07-30.
2entries
2years
1from disclosures
How it moved
Same theme, other companies
Option Agreement with Cyrano for a Treatment for Post-Viral Olfactory DysfunctionA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- 2026-07-30DroppedEarningsSuggests it is closing out
「Regarding CYR-064, a treatment for post-infectious olfactory dysfunction, we decided not to exercise the option.」
The decision not to exercise the option held with Cyrano for a treatment for post-infectious olfactory dysfunction was presented. - FY2025First statedAnnual report
「In February of that year, we entered into an option agreement with Cyrano for a treatment for post-viral olfactory dysfunction.」
An option agreement for a treatment for post-viral olfactory dysfunction was signed with Cyrano in February 2025.